Event Details

Zoom Webinar
United Kingdom

Start:March 19th, 2024 4:00 PMEnd:March 19th, 2024 4:45 PM

ARCS365 is one way that we aim to make some of the latest research and practice available to members throughout the year – it’s also a great way to gain some extra CPD points.

Booking: Members only, please sign into the website to book

Speaker: Sherman Silber

Title: Converting stem cells to germ cells

Date: Tuesday 19th March, 16:00 - 16:45


Dr. Sherman Silber, a renowned pioneer in microsurgery and infertility, is considered one of the world’s leading authorities on IVFmini-IVFsperm retrievalICSIvasectomy reversalmale infertilitytubal ligation reversalegg and embryo freezingovary transplantation and the reproductive biological clock.

For over 48 years Dr. Silber has originally developed all of the most popular fertility treatments used all around the world today.

He performed the world’s first microsurgical vasectomy reversal, as well as the first testicle transplant, in the 70’s and now in the current century, the world’s first ovary transplant. He was the first to develop the TESE and MESA techniques for retrieving testicular and epididymal sperm in azoospermic men. He headed the clinical MIT team that first mapped and sequenced the Y chromosome in infertile men and discovered the now famous DAZ gene for male fertility. His research includes also the study of reproduction and fertility in zoo animals and endangered species. Most recently he has perfected the preservation of fertility for cancer patients with ovarian freezing and transplantation and thereby figured out how to extend the reproductive biological clock of women. He has helped pioneer minimal ovarian stimulation to reduce IVF costs and eliminate complications while maintaining the very highest success rate, even in older women. He has even recently answered the age-old question of why the dinosaurs went extinct by extending his research on male infertility and the Y chromosome, discovering that the change in earth temperature 65,000,000 years ago led to the birth of a skewed male/female sex ratio.

He now heads the clinical team on the CHOSE project to transform skin biopsy cells into eggs and sperm in humans.

Dr. Silber went to medical school at the University of Michigan, did post-graduate training at Stanford University, and then again at the University of Michigan. From 1967 to 1969, he provided medical care via the U. S. Public Health Service to Eskimos, Indians, and Aleuts. Then he taught at the University of Melbourne Medical School in Australia, and later at the University of California Medical School in San Francisco. He is a scientific collaborator at MIT in Cambridge, Massachusetts, at the Kato Clinic in Tokyo, and at the University of Kyushu in Japan, and is a full professor at the University of Amsterdam, and at Sun Yat Sen University Medical School in China. His major clinical medical practice is in St. Louis, Missouri.


This talk will review our results with in vitro oogenesis from somatic cells.  This in vitro oogenesis from skin biopsy cells has given us a better understanding of ovarian longevity and primordial follicle recruitment in humans.  We have found that primordial follicle recruitment is triggered by tissue pressure gradients in the ovary cortex and medulla.  Increased extracellular matrix tissue pressure ( density ) holds the primordial follicle in meiotic arrest, preventing recruitment, and preventing all the germ cells from going through meiosis at once and depleting the ovary rapidly of all oocytes.  Therefore recruitment occurs first in the least dense inner tissue of the ovarian cortical medullary junction.  Ovary cortex transplantation results in a rapid over recruitment of primordial follicles because of the sudden decrease in tissue pressure.  Pregnancy with increased pressure on the ovary from the expanding uterus also shuts off primordial follicle recruitment and stabilizes the otherwise relentless decline with age of AMH levels.  Removing primordial follicles from their tissue matrix results in recruitment.  Artificially produced oocytes from stem cells immediately undergo meiosis and degenerate after no fertilization, just like in vivo. However, incubating these artificially produced oocytes in high pressure incubators arrests them in meiosis.  When they are removed from the high pressure incubator and placed in an incubator with normal atmosp